Search results for "PEPTIDE"

showing 10 items of 4589 documents

2012

Background and Purpose Diagnosis of paroxysmal atrial fibrillation (AF) can be challenging, but it is highly relevant in patients presenting with sinus rhythm and acute cerebral ischemia. We aimed to evaluate prospectively whether natriuretic peptide levels and kinetics identify patients with paroxysmal AF. Methods Patients with acute cerebral ischemia were included into the prospective observational Find-AF study. N-terminal pro brain-type natriuretic peptide (NT-proBNP), brain-type natriuretic peptide (BNP) and N-terminal pro atrial-type natriuretic peptide (NT-proANP) plasma levels were measured on admission, after 6 and 24 hours. Patients free from AF at presentation received 7 day Holt…

medicine.medical_specialtyMultidisciplinarymedicine.diagnostic_testbusiness.industrymedicine.drug_classArea under the curveIschemiaAtrial fibrillation030204 cardiovascular system & hematologymedicine.disease03 medical and health sciences0302 clinical medicineInternal medicineNatriuretic peptideCardiologyMedicineSinus rhythmcardiovascular diseasesbusinessProspective cohort studyElectrocardiographyStrokehormones hormone substitutes and hormone antagonists030217 neurology & neurosurgeryPLOS ONE
researchProduct

Link of the mechanisms of action of glatiramer acetate to its long-term clinical data

2009

A consequence of the long-term nature of progression in multiple sclerosis is that treatment needs to be provided over the long term. Gathering evidence for long term clinical efficacy, safety and patient acceptance of immunomodulatory therapies is thus a critically important issue. However, pivotal trials, which generally last no more than two years, cannot address this issue. Glatiramer acetate is the only immunomodulatory treatment for which prospective data is available covering a treatment period of over a decade. In the long-term extension of the pivotal trial of glatiramer acetate, 108 patients have been followed for a mean treatment duration of 10.1 years. At the end of the treatmen…

medicine.medical_specialtyMultiple SclerosisTimeSecondary PreventionHumansMedicineClinical efficacyGlatiramer acetateIntensive care medicineClinical Trials as Topicbusiness.industryMultiple sclerosisGlatiramer AcetatePrognosismedicine.diseaseTreatment periodTerm (time)Clinical trialTreatment OutcomeNeurologyAmbulatoryDisease ProgressionPhysical therapyObservational studyNeurology (clinical)PeptidesbusinessRisk Reduction BehaviorImmunosuppressive Agentsmedicine.drugJournal of the Neurological Sciences
researchProduct

A review of recent evidence in human studies of n-3 and n-6 PUFA intake on cardiovascular disease, cancer, and depressive disorders: does the ratio r…

2015

AbstractPolyunsaturated fatty acids (PUFAs) have been considered of great interest for human health due to their potential anti-inflammatory action that may protect from a number of chronic-degenerative diseases with an inflammatory pathogenesis. This review aimed to report the most updated evidence of both n-3 and n-6 PUFAs effect on cardiovascular disease, cancer, and depression in humans. Attention has been also paid to those studies exploring the effects of the ratio intake. Results from pooled analyses of human studies reported a general positive effect of n-3 PUFAs intake on all outcomes considered. In contrast, the role of n-6 PUFAs on human health needs to be better assessed in orde…

medicine.medical_specialtyN 6 pufachronic diseases inflammation polyunsaturated fatty acidsDiseaseBiologyBioinformaticsHuman healthInternal medicineFatty Acids Omega-6NeoplasmsFatty Acids Omega-3medicineHumansSettore MED/49 - Scienze Tecniche Dietetiche ApplicateDepression (differential diagnoses)chemistry.chemical_classificationDepressive DisorderHuman studiesfood and beveragesCancermedicine.diseaseEndocrinologychemistryCardiovascular Diseaseslipids (amino acids peptides and proteins)Food AnalysisFood SciencePolyunsaturated fatty acidInternational journal of food sciences and nutrition
researchProduct

The Peptide for Life Initiative: a call for action to provide equal access to the use of natriuretic peptides in the diagnosis of acute heart failure…

2021

n/a Funding Agencies|Applied Therapeutics; Innolife; Novartis PharmaceuticalsNovartis; Abbott DiagnosticsAbbott Laboratories; AstraZenecaAstraZeneca; AbbottAbbott Laboratories; Boehringer IngelheimBoehringer Ingelheim; Cardior Pharmaceuticals Gmbh; Ionis Pharmaceuticals, Inc.; Novo NordiskNovo Nordisk; RocheRoche Holding; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission; Swiss Heart Foundation; KTI; European UnionEuropean Commission; University of Basel; University Hospital Basel; Beckman Coulter; BRAHMS; Idorsia; NovartisNovartis; Ortho Clinical Diagnostics; Quidel; SiemensSiemens AG; Singulex; Sphingotec; CardioRenal

medicine.medical_specialtyNT-PROBNPMEDLINE030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemNatriuretic Peptide BrainmedicineMANAGEMENTHumansCardiac and Cardiovascular Systems030212 general & internal medicineNatriuretic PeptidesIntensive care medicineDYSPNEAHeart FailureKardiologibusiness.industryEmergency departmentASSOCIATIONmedicine.diseasePeptide FragmentsEMERGENCY-DEPARTMENT3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemEuropeAction (philosophy)Heart failurePeptidesCardiology and Cardiovascular MedicinebusinessAtrial Natriuretic FactorBiomarkers
researchProduct

Molecular anatomy of the neuro-immune connection.

1991

Light microscopic immunohistochemistry was employed to elucidate and compare the presence, distribution, and coexistence of various peptides, neuroendocrine markers and enzymes of the catecholamine pathway in nerves supplying lymphoid tissues in a variety of mammalian species. All lymphoid organs and tissues receive innervation by fibers containing dopamine-beta-hydroxylase and/or tyrosine hydroxylase, neural markers like protein gene product 9.5, synaptophysin and neurofilament and a varied spectrum of peptides. The prominent peptides were tachykinins (substance P, neurokinin A), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and vasoactive intestinal polypeptide/peptide his…

medicine.medical_specialtyNeurofilamentLymphoid TissueNeuroimmunomodulationSwineVasoactive intestinal peptideGuinea PigsPalatine TonsilFluorescent Antibody TechniqueSubstance PThymus GlandCalcitonin gene-related peptidechemistry.chemical_compoundMiceDogsBone MarrowInternal medicineNeural PathwaysmedicineAnimalsHumansNeuronsSheepTyrosine hydroxylasebiologyChemistryGeneral NeuroscienceGeneral MedicineAnatomyNeuropeptide Y receptorImmunohistochemistryRatsEndocrinologySynaptophysinbiology.proteinCatsNeurokinin ALymph NodesPeptidesSpleenThe International journal of neuroscience
researchProduct

Peripheral amplification of sweating - a role for calcitonin gene-related peptide

2006

Neuropeptides are the mediators of neurogenic inflammation. Some pain disorders, e.g. complex regional pain syndromes, are characterized by increased neurogenic inflammation and by exaggerated sudomotor function. The aim of this study was to explore whether neuropeptides have a peripheral effect on human sweating. We investigated the effects of different concentrations of calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and substance P (SP) on acetylcholine-induced axon reflex sweating in healthy subjects (total n = 18). All substances were applied via dermal microdialysis. The experiments were done in a parallel setting: ACh alone and ACh combined with CGRP, VIP …

medicine.medical_specialtyNeurogenic inflammationintegumentary systemPhysiologyVasoactive intestinal peptideNeuropeptideSubstance PCalcitonin gene-related peptideSudomotorchemistry.chemical_compoundEndocrinologychemistryCalcitoninInternal medicinemedicineAxon reflexThe Journal of Physiology
researchProduct

The neuro-B cell link of peptidergic innervation in the Bursa Fabricii

1991

The Bursa Fabricii, restricted to birds, specifically provides the microenvironment for B-cell maturation. The presence of nerve fibers containing immunopotent neuropeptides in immune organs opens interesting perspectives on the understanding of neuroimmune communication. As an organ for the development of only B-lymphocytes is not known in mammals, the contribution of a peptidergic innervation to the microenvironment of B-cells is not known. Therefore, we studied the peptidergic innervation of the Bursa Fabricii as an organ of B-cell maturation. Four different neuropeptides were found in nerve fibers of the Bursa Fabricii: tachykinins (TK), vasoactive intestinal peptide (VIP), galanin (GAL…

medicine.medical_specialtyNeuroimmunomodulationCalcitonin Gene-Related PeptideImmunologyVasoactive intestinal peptideNeuropeptideGalaninNerve fiberBiologyCalcitonin gene-related peptideMonocytesImmunoenzyme TechniquesBehavioral NeuroscienceBursa of FabriciusNerve FibersTachykininsInternal medicinemedicineAnimalsGalaninMedullaB cellB-LymphocytesEndocrine and Autonomic SystemsMacrophagesNeuropeptidesCell DifferentiationCell biologyEndocrinologymedicine.anatomical_structurePeripheral nervous systemPeptidesChickensVasoactive Intestinal PeptideBrain, Behavior, and Immunity
researchProduct

Migraine and cluster headache – the common link

2018

Abstract Although clinically distinguishable, migraine and cluster headache share prominent features such as unilateral pain, common pharmacological triggers such glyceryl trinitrate, histamine, calcitonin gene-related peptide (CGRP) and response to triptans and neuromodulation. Recent data also suggest efficacy of anti CGRP monoclonal antibodies in both migraine and cluster headache. While exact mechanisms behind both disorders remain to be fully understood, the trigeminovascular system represents one possible common pathophysiological pathway and network of both disorders. Here, we review past and current literature shedding light on similarities and differences in phenotype, heritability…

medicine.medical_specialtyNeurologyCluster headacheImplantable Neurostimulators/statistics & numerical dataPain medicineCalcitonin Gene-Related PeptideDeep Brain StimulationMigraine DisordersNitroglycerin/adverse effectsHypothalamuslcsh:MedicineTriptansReviewCalcitonin gene-related peptideBioinformatics03 medical and health sciencesNitroglycerin0302 clinical medicinemedicineHumans030212 general & internal medicineTryptamines/pharmacologyMigraineTrigeminovascular systembusiness.industryNeuromodulationCluster Headache/bloodCluster headacheAnti-CGRP (receptor) monoclonal antibodies – mAbsMigraine Disorders/bloodTrigeminovascular systemlcsh:RGeneral MedicineCalcitonin gene-related peptide (CGRP)medicine.diseaseDeep Brain Stimulation/statistics & numerical dataNeuromodulation (medicine)Tryptamines3. Good healthCalcitonin Gene-Related Peptide/antagonists & inhibitorsAnesthesiology and Pain MedicineImplantable NeurostimulatorsMigraineNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugThe Journal of Headache and Pain
researchProduct

Substance P Serum Degradation in Complex Regional Pain Syndrome – Another Piece of the Puzzle?

2021

In a previous study, we demonstrated that the serum peptidase system might be less efficient in complex regional pain syndrome (CRPS). Since the neuropeptide substanc P (SP) contributes to inflammation in CRPS, we now investigated the metabolism of SP in CRPS specifically. An SP metabolism assay was performed in 24 CRPS patients, which constitute a subgroup of our previous investigation on BK degradation. In addition, we included 26 healthy controls (24 newly recruited plus 2 from our previous investigation), and 13 patients after limb trauma, who did not fulfil the CRPS diagnostic criteria (trauma controls, TC) were included. We adapted a thin layer chromatography assay (TLC) to quantify S…

medicine.medical_specialtyNeuropeptideBradykininInflammationSubstance PPeptidyl-Dipeptidase ASubstance PBradykininchemistry.chemical_compoundInternal medicinemedicineHumansNeprilysinbiologybusiness.industryAngiotensin-converting enzymemedicine.diseaseAnesthesiology and Pain MedicineEndocrinologyComplex regional pain syndromeNeurologychemistrybiology.proteinNeurology (clinical)medicine.symptombusinessComplex Regional Pain SyndromesEx vivoPeptide HydrolasesThe Journal of Pain
researchProduct

Studies on the mechanism of PMN activation II. by triggering the alternative pathway of complement activation

1982

By means of cobra venom factor (CVF) it is demonstrated that the stimulation of hexosemonophosphate shunt (HMPS) of human polymorphonuclear leukocytes (PMN) by zymosan (Z) and dextran sulfate (DS) is caused by at least two modes of activation: (a) via activation caused by phagocytosis, (b) via activated alternative pathway of complement activation (APC). Active factors of APC presented with phagocytizable objects strongly enhance activation of PMN. The effect of APC can be observed in serum-containing as well as in serum-free cultures. It can be demonstrated that in serum-free cultures the factors of APC participating in the activation of PMN are supplied by monocytes. By the use of synthet…

medicine.medical_specialtyNeutrophilsPhagocytosisComplement Pathway AlternativeDose-Response Relationship ImmunologicStimulationMonocyteschemistry.chemical_compoundPhagocytosisInternal medicinemedicineHumansComplement ActivationHematologyChemistryDextran SulfateZymosanZymosanDextransComplement C3HematologyGeneral MedicinePeptide FragmentsCell biologyComplement systemDextran sulfateBiochemistryComplement C3aAlternative complement pathwayCobra venom factorBlut
researchProduct